David Hyman, MD

About Me

I am a gynecologic medical oncologist and Chief of the Early Drug Development service. In my clinical practice, I specialize in caring for women with gynecologic cancers including ovarian, endometrial (uterine), and cervical cancers. In addition, I lead a large multidisciplinary group of researchers that conduct a variety of early phase clinical studies where we study new drugs entering the clinic for the first time. My research focuses on the development of genomically selected targeted therapies. I had developed and led numerous global clinical trials of these genetically targeted cancer therapies, leading to eventual approval of several of these new drugs as routine therapies.

  • Clinical Expertise: Gynecologic Cancers (Ovarian, Endometrial, Cervical); Uterine Sarcomas; Clinical Trials (First-in-Human Phase I; Phase II)
  • Languages Spoken: English
  • Education: MD, Weill Cornell Medical College
  • Residencies: Internal Medicine - New York Presbyterian/Weill Cornell Medical College
  • Fellowships: Medical Oncology/Hematology - Memorial Sloan Kettering Cancer Center
  • Board Certifications: Internal Medicine; Medical Oncology


Visit PubMed for a full listing of David Hyman’s journal articles

Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.

Clinical Trials

Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.

Clinical Trials Led by David Hyman

Clinical Trials Co-Investigated by David Hyman


Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.

Learn more Arrow rightAn icon showing an arrow pointing to the right.